Spectrum and functional validation of PSMB5 mutations in multiple myeloma

[1]  T. Arndt.  Crystal , 2019, Springer Reference Medizin.

[2]  G. Morgan,et al.  Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma , 2017, Leukemia.

[3]  Yuan-Xiao Zhu,et al.  CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma , 2017, Molecular Cancer Therapeutics.

[4]  R. Fonseca,et al.  Trends in overall survival and costs of multiple myeloma, 2000–2014 , 2016, Leukemia.

[5]  R. Fonseca,et al.  Genomic Characterization of High-Count MBL Cases Indicates that Early Detection of Driver Mutations and Subclonal Expansion are Predictors of Adverse Clinical Outcome , 2016, Leukemia.

[6]  L. Garraway,et al.  Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers , 2016, Proceedings of the National Academy of Sciences.

[7]  Erich A. Peterson,et al.  Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. , 2016, Blood.

[8]  H. Goldschmidt,et al.  Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. , 2016, Blood.

[9]  Ricardo A. Mata,et al.  The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design , 2016, Science.

[10]  B. Everts,et al.  Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism , 2016, Leukemia.

[11]  G. Ahmann,et al.  Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients , 2016, Blood Cancer Journal.

[12]  H. Keun,et al.  Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97 , 2015, Cell Death and Disease.

[13]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Marc L. Mendillo,et al.  Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome , 2015, eLife.

[15]  H. Einsele,et al.  Loss of Serum and Glucocorticoid-Regulated Kinase 3 (SGK3) Does Not Affect Proliferation and Survival of Multiple Myeloma Cell Lines , 2015, PloS one.

[16]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[17]  J. Sacchettini,et al.  Crystal structure of the human 20S proteasome in complex with carfilzomib. , 2015, Structure.

[18]  M. Groll,et al.  Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914. , 2015, Structure.

[19]  N. Potter,et al.  Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma , 2014, Leukemia.

[20]  R. Deshaies,et al.  p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition , 2013, bioRxiv.

[21]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[22]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[23]  A Rosenwald,et al.  Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules , 2013, Blood Cancer Journal.

[24]  G. Mulligan,et al.  Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. , 2012, Blood.

[25]  Michael L. Wang,et al.  Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. , 2012, Blood.

[26]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[27]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[28]  G. Peters,et al.  Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis , 2012, Journal of Pharmacology and Experimental Therapeutics.

[29]  J. Naval,et al.  Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy. , 2012, Leukemia research.

[30]  S. Demo,et al.  Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma Cells , 2011, PloS one.

[31]  Jianmin Wang,et al.  Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen. , 2011, Experimental hematology.

[32]  J. Keats,et al.  RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. , 2009, Blood.

[33]  R. Deshaies,et al.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. , 2010, Molecular cell.

[34]  Seamus J. Martin,et al.  Expression, purification and use of recombinant annexin V for the detection of apoptotic cells , 2009, Nature Protocols.

[35]  G. Peters,et al.  Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. , 2008, Blood.

[36]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[37]  D. Chauhan,et al.  Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. , 2003, Cancer research.